Day: March 8, 2023

Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas

Initiation of Phase I/II Clinical Trial (Starlight-1) Expected to Occur in Second Half of 2023 EMERYVILLE, Calif. and NEW YORK, March 9, 2023 /PRNewswire/ — Estrella Biopharma, Inc. (“Estrella”), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer with safe, […]

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

MELBOURNE, Australia, March 9, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 – 13 March 2023. Further data from Telix’s […]

ETAO International Entered Into Standby Equity Purchase Agreement of Up To $150 Million with YA II PN, Ltd.

NEW YORK, March 9, 2023 /PRNewswire/ — ETAO International Co., Ltd. (“ETAO” or the “Company”) announced on February 24, 2023, ETAO and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the “Investor”) managed by Yorkville Advisors Global, LP (the “Investment Manager”), entered into a Standby Equity Purchase Agreement (the “SEPA”). The Investor is […]

Humane raises $100m in Series C round as it builds device and services platform for the AI era

$100m Series C round led by Kindred Ventures, with significant participation by SK Networks, Microsoft, LG Technology Ventures, Volvo Cars Tech Fund, Top Tier Capital, Hudson Bay Capital, and Socium Ventures and existing investors Tiger Global, Qualcomm Ventures, Valia Ventures, Forerunner Ventures, Lachy Groom, and Sam Altman, Founder of OpenAI Strategic technology partners and collaborators […]

Back To Top